Ardelyx Partners with LPGA to Tackle Digestive Health Stigma
Event summary
- Ardelyx and the LPGA announced a multi-year partnership on February 24, 2026, making Ardelyx the official corporate pharmaceutical marketing partner of the LPGA Tour.
- The partnership aims to break the stigma around digestive health issues, particularly irritable bowel syndrome with constipation (IBS-C), which affects over 90% of women.
- Ardelyx will activate across key LPGA moments, including onsite experiences, custom storytelling, and digital engagement.
- The collaboration will focus on educating and empowering patients to take control of their health through open conversations and proactive measures.
The big picture
This partnership aligns Ardelyx's mission to improve digestive health with the LPGA's platform to empower women. It reflects a broader trend in the biopharmaceutical industry to leverage sports partnerships for health awareness campaigns. The collaboration aims to address the significant unmet medical needs in digestive health, particularly among women, who often face societal taboos and stigma.
What we're watching
- Patient Engagement
- How Ardelyx's partnership with the LPGA will impact patient engagement and awareness of IBS-C.
- Market Expansion
- Whether the partnership can help Ardelyx expand its market reach and commercialize its products more effectively.
- Partnership Effectiveness
- The pace at which the partnership activations and initiatives will be implemented and their effectiveness in achieving the stated goals.
Related topics